Jonathan Rubin
Hoofd Techniek/Wetenschap/O&O bij SUPERNUS PHARMACEUTICALS, INC.
Vermogen: 2 M $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Jack Khattar | M | 62 | 19 jaar | |
Charles Newhall | M | 79 | 19 jaar | |
Georges Gemayel | M | 64 | 9 jaar | |
John Siebert | M | 84 | 13 jaar | |
Frederick Hudson | M | 78 | 14 jaar | |
Carrolee Barlow | M | 60 | 6 jaar | |
Padmanabh P. Bhatt | M | 66 | 19 jaar | |
Frank Mottola | M | 52 | 19 jaar | |
Bethany Sensenig | F | 48 | 1 jaar | |
Timothy Dec | M | 66 | 3 jaar | |
Kevin T. Anderson | M | 61 | 12 jaar | |
Bryan A. Roecklein | M | - | 9 jaar | |
Todd Horich | M | - | 6 jaar | |
Taylor Raiford | M | - | 9 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Udi Gilboa | M | 57 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 6 jaar |
David Baker | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 jaar |
Yuval Yanai | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 1 jaar |
Joao Siffert | M | 60 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Arieh Ben-Yosef | M | 71 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 3 jaar |
Tomer Berkovitz | M | 44 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | 4 jaar |
Amir Efrati | M | 50 |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Tami Martin | F | 68 | 16 jaar | |
James Kelly | M | 58 | 1 jaar | |
Stefan Schwabe | M | 72 | 8 jaar | |
Hagit Marchaim | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Orli Tori | M | - |
Alcobra Ltd.
Alcobra Ltd. Pharmaceuticals: MajorHealth Technology Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel. | - |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 17 | 65.38% |
Israël | 9 | 34.62% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jonathan Rubin
- Persoonlijk netwerk